产品名称
STAT3抑制剂III，WP1066, STAT3 Inhibitor III, WP1066, CAS 857064-38-1, is a cell-permeable AG490 tyrphostin analog that acts as a STAT3 pathway inhibitor. A potent anti-tumor agent.
质量水平
方案
≥97% (HPLC)
表单
solid
制造商/商品名称
Calbiochem®
储存条件
OK to freeze
protect from light
颜色
off-white
溶解性
DMSO: 10 mg/mL
ethanol: 5 mg/mL
运输
ambient
储存温度
2-8°C
SMILES字符串
Brc1nc(ccc1)\C=C(\C(=O)N[C@@H](C)c2ccccc2)/C#N
InChI
1S/C17H14BrN3O/c1-12(13-6-3-2-4-7-13)20-17(22)14(11-19)10-15-8-5-9-16(18)21-15/h2-10,12H,1H3,(H,20,22)/b14-10+/t12-/m0/s1
InChI key
VFUAJMPDXIRPKO-LQELWAHVSA-N
一般描述
一种细胞渗透性AG 490（目录号658401）酪磷蛋白类似物，在体外培养（使用U87-MG和U373-MG进行生存能力试验时，IC50分别为5.6和3.7 µM；在10 µM时对非肿瘤NHA无抑制作用）和小鼠体内培养中，作为有效的STAT3途径抑制剂和比AG 490更有效的抗肿瘤剂抑制恶性胶质瘤生长。显示在小鼠体内能跨越血脑屏障。也可提供InSolution格式（目录号573129）。
一种细胞渗透性AG 490（目录号658401）酪磷蛋白类似物，在体外培养（使用U87-MG和U373-MG进行生存能力试验时，IC50分别为5.6和3.7 µM；在10 µM时对非肿瘤NHA无抑制作用）和小鼠体内培养中，作为有效的STAT3途径抑制剂和比AG 490更有效的抗肿瘤剂抑制恶性胶质瘤生长。显示在小鼠体内能跨越血脑屏障。
生化/生理作用
主靶
STAT3通路
STAT3通路
产物不与ATP竞争。
可逆：否
细胞可渗透性：是
靶标IC50：分别为5.6和3.7 µM，在使用U87-MG和U373-MG的活性试验中，抑制恶性胶质瘤生长
包装
用惰性气体包装
制备说明
复溶后，等分并冷冻保存（-20°C）。贮备溶液在-20°C下可稳定保存至多6个月。
其他说明
Iwamaru, A., et al. 2007.Oncogene,26, 2435.
法律信息
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
免责声明
毒性：刺激性（B）
储存分类代码
11 - Combustible Solids
WGK
WGK 2
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Alicia Haydo et al.
EMBO reports, 24(12), e56964-e56964 (2023-11-08)
Glioblastoma is a very aggressive tumor and represents the most common primary brain malignancy. Key characteristics include its high resistance against conventional treatments, such as radio- and chemotherapy and its diffuse tissue infiltration, preventing complete surgical resection. The analysis of
Meng Chi et al.
Annals of translational medicine, 8(8), 531-531 (2020-05-16)
Dexmedetomidine (DEX), a highly selective α2-adrenergic receptor agonist, has been reported to increase the malignancy of breast cancer cells in vitro and stimulate tumor growth in mice. Transmembrane protease serine 2 (TMPRSS2) demonstrates proteolytic activity, resulting in degradation of the
Eun-Ji Lim et al.
Cell death & disease, 13(4), 417-417 (2022-04-30)
Colorectal cancer (CRC) has a 5-year survival rate of <10%, as it can metastasize to the lungs and liver. Anticancer drugs and targeted therapies used to treat metastatic colorectal cancer have insufficient therapeutic efficacy and are associated with complications. Therefore
In-Hye Ham et al.
International journal of oncology, 61(1) (2022-05-28)
The present study aimed to investigate whether the Janus‑activated kinase (JAK)/signal transducer and activator of transcription 3 (STAT3) signaling pathway is a critical mechanism underlying the cancer‑associated fibroblast (CAF)‑induced chemoresistance of gastric cancer (GC). In addition, the present study tried to
Ahmad Sharanek et al.
Cell reports, 36(9), 109647-109647 (2021-09-02)
Brain tumor stem cells (BTSCs) and intratumoral heterogeneity represent major challenges in glioblastoma therapy. Here, we report that the LGALS1 gene, encoding the carbohydrate binding protein, galectin1, is a key regulator of BTSCs and glioblastoma resistance to therapy. Genetic deletion
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持